Novavax (NVAX) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Novavax (NVAX) over the last 16 years, with Q3 2025 value amounting to $3.9 million.
- Novavax's Gains from Investment Securities rose 25286.62% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.8 million, marking a year-over-year increase of 33936.12%. This contributed to the annual value of $21.8 million for FY2024, which is 2024.5% down from last year.
- Latest data reveals that Novavax reported Gains from Investment Securities of $3.9 million as of Q3 2025, which was up 25286.62% from $21.5 million recorded in Q2 2025.
- Novavax's Gains from Investment Securities' 5-year high stood at $64.0 million during Q4 2021, with a 5-year trough of -$16.6 million in Q1 2025.
- In the last 5 years, Novavax's Gains from Investment Securities had a median value of $10.3 million in 2021 and averaged $14.7 million.
- As far as peak fluctuations go, Novavax's Gains from Investment Securities soared by 346264.04% in 2021, and later crashed by 48896.25% in 2024.
- Quarter analysis of 5 years shows Novavax's Gains from Investment Securities stood at $64.0 million in 2021, then dropped by 25.52% to $47.7 million in 2022, then plummeted by 95.14% to $2.3 million in 2023, then surged by 677.19% to $18.0 million in 2024, then tumbled by 78.48% to $3.9 million in 2025.
- Its last three reported values are $3.9 million in Q3 2025, $21.5 million for Q2 2025, and -$16.6 million during Q1 2025.